NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

Meirluc,

Look at the patents, they clearly covered pneumonia. I don't believe they initially choose pneumonia to go after approval as I think such a trial would have been dramatically larger as so many people get pneumonia, and most survive, though it's still a major killer. With Covid-19 deaths of those on ventilators is so high they should easily show a major benefit.

From what I've read from the few cases sited where it was given for compassionate use, by the time patients go on ventilator, other organs besides the lungs are also damaged. PLX-PAD has been shown to achieve benefits in the other damaged organs. I believe it's being administered into muscle not specifically in the organs involved, much as it is in the CLI trial, I'm not technically knowledgeable, so I simply see the placental stem cells as miracle workers that find something wrong and work to fix it.

I believe there are parallels, and differences between PSTI and NWBO. While both use cells from people to create their products, NWBO's are cells from the specific patient, whereas PSTI's are placental. I do believe that if NWBO were looking to produce greater quantities of their personalized vaccines, they might find that it could be done in the 3-D bioreactors that PSTI has developed and patented. As I understand it, they are far superior to other similar bioreactors, and they're what leads them to being able to get 20K doses from a single placenta. I don't believe that NWBO needs anything close to that many doses, but some increase may be of benefit to the patients.

As I've indicated, I don't technically understand all that they're doing, and don't try to get a medical education at my age, just trying to have a laymen's understanding of what's happening. I may be off in my judgement that the two technologies might benefit from one another, time will tell about that.

From what I gather, if one of the other companies products that use a bioreactor is found to be successful, and mass production is planned, they may be smart to consider licensing the use of the PSTI's 3-D bioreactor over those currently available to increase the output of product.

Gary